저널: Breast Cancer Research and Treatment Website: 설명: resistance(1) ErbB(1) Metastatic breast cancer(1) Afatinib(1) HER2(1) Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trialarticle Published on 2022-02-092024-09-02 Journal: Breast Cancer Research and Treatment [Category] 대상포진, [키워드] Afatinib ErbB HER2 Metastatic breast cancer resistance [DOI] 10.1007/s10549-021-06449-4 PMC 바로가기 [Article Type] article Delayed type hypersensitivity response to recall antigens does not accurately reflect immune competence in advanced stage breast cancer patients지연형 과민반응이 재콜 항원에 대한 반응은 진행된 유방암 환자에서 면역 능력을 정확하게 반영하지 않는다.journal-article Published on 2002-07-012024-08-03 Journal: Breast Cancer Research and Treatment [Category] 파상풍, [DOI] 10.1023/a:1016009317796 [Article Type] journal-article
Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trialarticle Published on 2022-02-092024-09-02 Journal: Breast Cancer Research and Treatment [Category] 대상포진, [키워드] Afatinib ErbB HER2 Metastatic breast cancer resistance [DOI] 10.1007/s10549-021-06449-4 PMC 바로가기 [Article Type] article
Delayed type hypersensitivity response to recall antigens does not accurately reflect immune competence in advanced stage breast cancer patients지연형 과민반응이 재콜 항원에 대한 반응은 진행된 유방암 환자에서 면역 능력을 정확하게 반영하지 않는다.journal-article Published on 2002-07-012024-08-03 Journal: Breast Cancer Research and Treatment [Category] 파상풍, [DOI] 10.1023/a:1016009317796 [Article Type] journal-article